Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

Pulmatrix closed a private placement of Series B Preferred Stock with an affiliate of Eos SENOLYTIX, raising gross proceeds of approximately $1 million. The transaction is part of the planned merger between the two companies, with the preferred stock convertible into common stock at $2.20 per share.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.